In vascular fibroblasts, we identified significant regulatory effects of enhancers harboring CAD risk variants on MTAP, DMRTA1, and CDKN2B expression (Figure 2E; Table 2, Figure S 6A). The gene discussed is CDKN2B; the disease is coronary artery disorder.